Novo Nordisk shares dropped due to CagriSema trial results but have long-term upside. Learn why NVO stock is a Strong Buy ...

Compounded weight-loss medications, such as those promoted in the Hims & Hers commercial, aren’t approved by the Food and Drug Administration.

Research links weight loss medications like Ozempic and Zepbound to certain serious eye conditions.

Ozempic is synonymous with weight loss for many people. Doctors explain benefits and risks of semaglutide and other GLP-1 ...

In the glittering world of celebrity-endorsed weight loss transformations and viral before-and-after photos, a darker narrative is emerging from the shadows ...

Other GLP-1 agonists, including Zepbound, can cause hair loss ... Telogen effluvium (a type of hair loss) may also occur after weight loss. Some of the GLP-1 agonists are used for weight loss.

After pre-announcing that its full-year revenue would come in below its original guidance, Eli Lilly (NYSE: LLY) announced ...

People taking weight-loss drugs say they are losing their sight. Science is trying to figure out why - There’s no direct link ...

Zepbound, another weight-loss drug, was taken off the compounding list in December after manufacturer Eli Lilly increased production. The same is expected to happen soon for Wegovy, which is made ...

Its lineup features several blockbusters, including its popular diabetes and weight loss medicines, Mounjaro and Zepbound. It's true that these drugs' sales are not increasing quite as fast as ...

Now, one type of weight-loss medication is proving helpful with another health issue. In a study published Feb. 12 in JAMA ...